AstraZeneca Shows 79% Efficacy in U.S. Trial without Increased Risk of Blood Clots
AstraZeneca has shown 79% efficacy in preventing symptomatic illness in the U.S. trial with no increased risk of blood clots.
AstraZeneca has shown 79% efficacy in preventing symptomatic illness in the U.S. trial with no increased risk of blood clots.
23 มี.ค. 2564

AstraZeneca has shown 79% efficacy in preventing symptomatic illness in the U.S. trial with no increased risk of blood clots and 100% efficacy against severe or critical disease and hospitalization, said the company in a statement.
 
This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had a 2:1 randomization of vaccine to placebo.
Vaccine efficacy was consistent across ethnicity and age. Notably, in participants aged 65 years and over, vaccine efficacy was 80%.
The vaccine was well-tolerated, and the independent data safety monitoring board (DSMB) identified no safety concerns related to the vaccine.
 
The World Health Organization (WHO) has urged people to continue the vaccination, saying the data of the AstraZeneca shot did not show the potential of developing blood clots.
Germany, France, Italy and Spain are among European countries to resume the Oxford-AstraZeneca jab after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is both safe and effective.